RPHM Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
Reneo Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
RPHM Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Reneo Pharmaceuticals, Inc. Key Details
About RPHM
- Founded
- 2014
- Employees
- 8
- CEO
- WebsiteView website
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company’s lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
